1. Home
  2. SE vs ALNY Comparison

SE vs ALNY Comparison

Compare SE & ALNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Sea Limited each representing one

SE

Sea Limited each representing one

HOLD

Current Price

$124.67

Market Cap

74.0B

ML Signal

HOLD

Logo Alnylam Pharmaceuticals Inc.

ALNY

Alnylam Pharmaceuticals Inc.

HOLD

Current Price

$391.28

Market Cap

60.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SE
ALNY
Founded
2009
2002
Country
Singapore
United States
Employees
N/A
N/A
Industry
Other Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
74.0B
60.1B
IPO Year
2017
2004

Fundamental Metrics

Financial Performance
Metric
SE
ALNY
Price
$124.67
$391.28
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
12
27
Target Price
$191.91
$484.39
AVG Volume (30 Days)
5.1M
1.1M
Earning Date
11-11-2025
10-30-2025
Dividend Yield
N/A
N/A
EPS Growth
1416.22
N/A
EPS
2.29
0.33
Revenue
$21,037,037,000.00
$3,210,070,000.00
Revenue This Year
$37.28
$69.60
Revenue Next Year
$24.30
$42.67
P/E Ratio
$54.48
$1,205.23
Revenue Growth
35.84
53.24
52 Week Low
$99.50
$205.87
52 Week High
$199.30
$495.55

Technical Indicators

Market Signals
Indicator
SE
ALNY
Relative Strength Index (RSI) 35.02 31.31
Support Level $123.16 $387.03
Resistance Level $129.10 $479.79
Average True Range (ATR) 4.58 16.69
MACD -0.09 -6.48
Stochastic Oscillator 18.99 4.58

Price Performance

Historical Comparison
SE
ALNY

About SE Sea Limited each representing one

Sea started as a gaming business, Garena, but in 2015 expanded into e-commerce. Sea operates Southeast Asia's largest e-commerce company, Shopee, in terms of gross merchandise value. Shopee is a hybrid C2C and B2C marketplace platform operating in Indonesia, Taiwan, Vietnam, Thailand, Malaysia, the Philippines, and Brazil. For Garena, Free Fire is the key revenue generating game. Sea's third business, SeaMoney, provides lending, payment, digital banking, and insurance services.As of March 31, 2025, Forrest Xiaodong Li, the founder, chairman and CEO, owned 59.1% of voting power. Tencent owned 18.5% of issued shares with no voting power.

About ALNY Alnylam Pharmaceuticals Inc.

Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.

Share on Social Networks: